Rising demand for human biologics cannot be fulfilled by currently used mammalian cell culture production platforms, as these platforms are highly expensive and have limited scalability. However, recent developments in plant expression vectors, downstream processing, and glycoengineering have established plants as a superior alternative to biologic production. Plants not only offer the traditional benefits of proper eukaryotic protein modification, but also have the potential to develop biologics at a lower cost with high scalability. They increase the production of biologics at unprecedented speed and also helps in controlling potential pandemics for better efficacy or safety.

Plant-based biologics is expected to be the next major commercial development in the field of biotechnology. Some of the advantages offered in terms of product safety, production scale and economy, ease of storage, and distribution cannot be fulfilled at same time by any other current commercial system. They also provide the opportunity to supply low-cost drugs and vaccines to the emerging economies.

Usage of plant-based cell line instead of mammal cell lines to produce biologic drugs came to the forefront when various companies were trying to scale up the alternative process in an effort to produce treatment for Ebola. The approval of the first plant-made biologic (PMB) - taliglucerase alfa for injection by the U.S. Food and Drug Administration (USFDA) for treating Gaucher's disease in 2012 proclaimed a new era for PMBs and triggered the innovation in the field of biopharmaceuticals.

Plant-based Biologics Market – Dynamics

Increasing demand for biologics for various chronic diseases and rising investment in R&D for the production of biologics is expected to contribute significantly to the growth of plant-based biologics market. According to Biotechnology Innovation Organization (BIO) 2015, over 250 biologic therapies and vaccines have changed the lives of hundreds of millions of patients. Moreover, according to the same source, over 900 biologics are currently (2018) under the stage of development for over 100 diseases in the U.S. According to the Pharmaceutical Research and Manufacturers of America (PhRMA), 2016, member companies invested around US$ 58.8 billion in research and development in 2015, of which, majority of the investment was made by all the biopharmaceutical companies in the U.S. for the treatment of rare diseases.

Many biopharmaceutical companies are entering into developing plant-made pharmaceuticals using various plants such as tobacco, duckweed, moss, alfalfa, and other plants, which is expected to propel growth of the plant-based biologics market. For instance, in September 2015, LeafBio, Inc., the commercial partner of Mapp Biopharmaceutical, Inc. (Mapp), was granted fast track designation by the U.S. Food and Drug Administration (FDA) for their plant-made drug called ZMapp for the treatment of Ebola virus disease.

However, stringent regulatory guidelines for the production of plant-based biologics is one of the major factors restraining growth of the plant-based biologics market. Moreover, concern regarding contamination and environmental risks is another factor restraining growth of the market.

Plant-based Biologics Market – Regional Analysis

On the basis of region, the global plant-based biologics market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa.

North America is expected to be the most lucrative region in the plant-based biologics market over the forecast period. This is owing to the presence of various private and government research organizations focused on R&D activities to develop plant-based biologics in this region. For instance, Fraunhofer Center for Molecular Biotechnology completed phase I clinical trials for the study of safety and immunogenicity of plant-derived recombinant protective antigen (Biological: PA83-FhCMB) for anthrax vaccine in healthy adults in year 2015. Furthermore, key players in North America are focused on conducting clinical trials to develop plant-based biologics for the treatment of various chronic diseases, which is further expected to drive growth of the plant-based biologics market in this region.

Plant-based Biologics Market – Competitive Landscape

Major players operating in the global plant-based biologics market include PlantForm, IBio Inc., Mapp Biopharmaceutical, Inc., Pfizer Inc., Ventria Bioscience, Medicago Inc., Greenovation Biotech GmbH, Kentucky BioProcessing, PhycoBiologics Inc., Synthon, Fraunhofer IME, Healthgen, PlanetBiotechnology, and Icon Genetics GmbH. Key players in plant-based biologics market are focused on adopting market strategies such as collaborations, mergers & acquisitions, and new product development, in order to retain dominant position in the market. For instance, in August 2017, Japanese company named Denka acquired German plant biotech Icon Genetics Inc. for approximately US$ 85.0 million. This acquisition will help Denka to focus on research and development in the vaccines and diagnostic reagents business and to continue development of new biopharmaceuticals, including biosimilar and ‘biobetter’ antibodies.

Plant-based Biologics Market – Taxonomy

On the basis of plant system, the global plant-based biologics market is segmented into:

  • Leaf-based 
  • Seeds-based 
  • Fruits-based 
  • Tubers-based 
  • Others

On the basis of source, the global plant-based biologics market is segmented into:

  • Carrot
  • Tobacco
  • Duckweed
  • Rice
  • Moss
  • Alfalfa
  • Others

On the basis of geography, the global plant-based biologics market is segmented into:

  • North America
  • Latin America
  • Europe
  • Asia Pacific
  • Middle East
  • Africa

Research Methodology

Coherent Market Insights followsa comprehensive research methodology focused on providing the most precise market analysis. The company leverages a data triangulation model which helps company to gauge the market dynamics and provide accurate estimates. Key components of the research methodologies followed for all our market reports include:

  • Primary Research (Trade Surveys and Experts Interviews)
  • Desk Research
  • Proprietor Data Analytics Model

In addition to this, Coherent Market Insights has access to a wide range of the regional and global reputed paid data bases, which helps the company to figure out the regional and global market trends and dynamics. The company analyses the industry from the 360 Degree Perspective i.e. from the Supply Side and Demand Side which enables us to provide granular details of the entire ecosystem for each study. Finally, a Top-Down approach and Bottom-Up approach is followed to arrive at ultimate research findings.

Data Triangulation Methodology | Coherent Market Insights

Coherent Market Insights desk research is based on a principle set of research techniques:

  • National level desk research: It Includes research analysis of regional players, regional regulatory bodies, regional trade associations, and regional organization.
  • Multinational level desk research: The research team keeps a track of multinational players, global regulatory bodies, global trade associations, and global organization.

Coherent Market Insights has a large amount of in-house repository of industry database. This is leveraged as a burner for initiating a new research study. Key secondary sources include:

  • Governmental bodies, National and international social welfare institutions, and organizations creating economic policies among others.
  • Trade association, National and international media and trade press.
  • Company Annual reports, SEC filings, Corporate Presentations, press release, news, and specification sheet of manufacturers, system integrators, brick and mortar - distributors and retailers, and third party online commerce players.
  • Scientific journals, and other technical magazines and whitepapers.

Market Analysis | Coherent Market Insights

Preliminary Data Mining

The raw data is obtained through the secondary findings, in house repositories, and trade surveys. It is then filtered to ensure that the relevant information including industry dynamics, trends, and outlook is retained for further research process.

Data Standardization

Holistic approach is used to ensure that the granular and uncommon parameters are taken into consideration to ensure accurate results. The information from the paid databases are further combined to the raw data in order to standardize it.

Coherent Statistical model

We arrive at our final research findings through simulation models. Coherent Data Analytics Model is a statistical tool that helps company to forecast market estimates. Few of the parameters considered as a part of the statistical model include:

  • Micro-economic indicators
  • Macro-economic indicators
  • Environmental indicators
  • Socio-political indicators
  • Technology indicators

Data Processing

Once the findings are derived from the statistical model, large volume of data is process to confirm accurate research results. Data analytics and processing tools are adopted to process large chunk of collected informative data. In case, a client customizes the study during the process, the research finding till then are benchmarked, and the process for new research requirement is initiated again.

Data Validation

This is the most crucial stage of the research process. Primary Interviews are conducted to validate the data and analysis. This helps in achieving the following purposes:

  • It provides first-hand information on the market dynamics, outlook, and growth parameters.
  • Industry experts validates the estimates which helps the company to cement the on-going research study.
  • Primary research includes online surveys, face-to face interviews, and telephonic interviews.

The primary research is conducted with the ecosystem players including, but not limited to:

  • Raw Material Suppliers
  • Manufacturers
  • System Integrators
  • Distributors
  • End-users